Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
作者信息
Kansagara Devan, Mackey Katherine, Vela Kathryn
机构信息
VA Portland Health Care System, Portland, Oregon (D.K., K.M., K.V.).
出版信息
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
2
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
3
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
4
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报4：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.
5
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
6
Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.血管紧张素转换酶2与炎症消退：支持继续使用处方血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Mayo Clin Proc. 2020 Jul;95(7):1552-1553. doi: 10.1016/j.mayocp.2020.05.001. Epub 2020 May 21.
7
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与冠状病毒
J Hypertens. 2020 Jun;38(6):1190-1191. doi: 10.1097/HJH.0000000000002469.
8
COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.COVID-19 与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂治疗。
Ann Intern Med. 2020 Aug 4;173(3):237-238. doi: 10.7326/M20-3047. Epub 2020 May 15.
9
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.对近期有关血管紧张素转换酶2（ACE2）和肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关性的评论的回应
Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.
10
Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.在患有非新冠病毒感染相关性脓毒症的重症监护病房患者中，血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的长期使用率很高，但死亡风险会适度增加。
Hypertension. 2020 Jun;75(6):e15-e16. doi: 10.1161/HYPERTENSIONAHA.120.15178. Epub 2020 Apr 10.
引用本文的文献
1
Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation.《系统综述与Meta分析报告的规范（PRISMA）2020声明：针对实时系统综述的扩展（PRISMA-LSR）》：清单及解释
BMJ. 2024 Nov 19;387:e079183. doi: 10.1136/bmj-2024-079183.
2
Past, present and future of living systematic review: a bibliometrics analysis.生命系统综述的过去、现在和未来：文献计量学分析。
BMJ Glob Health. 2022 Oct;7(10). doi: 10.1136/bmjgh-2022-009378.
3
3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study.密歇根州东南部 3219 名住院 COVID-19 患者：一项回顾性病例队列研究。
BMJ Open. 2021 Apr 7;11(4):e042042. doi: 10.1136/bmjopen-2020-042042.
4
Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 患者死亡率、严重程度或 SARS-CoV-2 检测阳性率的关系：荟萃分析。
Sci Rep. 2021 Mar 3;11(1):5012. doi: 10.1038/s41598-021-84678-9.
5
Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic.使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂的2019冠状病毒病患者的死亡率、严重程度及住院情况：一项基于对第一波疫情反应对国家进行分层的荟萃分析
Healthcare (Basel). 2021 Jan 28;9(2):127. doi: 10.3390/healthcare9020127.
6
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.血管紧张素转换酶 2（ACE2）药理学调控的综合指南，该酶是 SARS-CoV-2 的进入受体。
Pharmacol Ther. 2021 May;221:107750. doi: 10.1016/j.pharmthera.2020.107750. Epub 2020 Dec 1.
7
[COVID-19 and the kidneys].[新型冠状病毒肺炎与肾脏]
Nephrologe. 2020;15(4):210-215. doi: 10.1007/s11560-020-00444-4. Epub 2020 Jun 26.
本文引用的文献
1
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用与新型冠状病毒病 2019（COVID-19）检测阳性的关联。
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855.
2
Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.撤稿声明：2019年冠状病毒病中的心血管疾病、药物治疗和死亡率。《新英格兰医学杂志》。DOI：10.1056/NEJMoa2007621
N Engl J Med. 2020 Jun 25;382(26):2582. doi: 10.1056/NEJMc2021225. Epub 2020 Jun 4.
3
Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.肾素-血管紧张素-醛固酮系统抑制剂与韩国 2019 冠状病毒病（COVID-19）相关结局的关联：一项全国基于人群的队列研究。
Clin Infect Dis. 2020 Nov 19;71(16):2121-2128. doi: 10.1093/cid/ciaa624.
4
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对成人 SARS-CoV-2 感染的风险和影响：一项实时系统评价。
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.
5
Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication.患有糖尿病和 COVID-19 患者的临床特征和转归与降糖药物的关系。
Diabetes Care. 2020 Jul;43(7):1399-1407. doi: 10.2337/dc20-0660. Epub 2020 May 14.
6
The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension.肾素-血管紧张素系统（RAS）阻滞剂对高血压COVID-19患者临床特征的影响。
Ann Transl Med. 2020 Apr;8(7):430. doi: 10.21037/atm.2020.03.229.
Zotero 插件